Quick Takeaways
- SAMLYN CAPITAL, LLC filed SCHEDULE 13G/A for Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share (INZY).
- Disclosed ownership: 0%.
- Date of event: 31 Dec 2024.
SAMLYN CAPITAL, LLC - 31 Dec 2024 SCHEDULE 13G/A Report for Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share (INZY)
- Filing Manager
- SAMLYN CAPITAL, LLC
- Reporting Manager
- Samlyn Capital, LLC
- Symbol
- INZY
- Disclosed Ownership
- 0 shares
- Ownership
- 0%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 13:59:36 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"SAMLYN CAPITAL, LLC disclosed 0% ownership in Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share (INZY) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 13:59.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Samlyn Capital, LLC | 0% | 0 | 0 | 0 | By: Samlyn, LP, its sole member, By: Samlyn GP, LLC, its general partner, By: /s/ Robert Pohly | Robert Pohly/Managing Member* | |
| Samlyn, LP | 0% | 0 | 0 | 0 | By: Samlyn GP, LLC, its general partner, By: /s/ Robert Pohly | Robert Pohly/Managing Member* | |
| Robert Pohly | 0% | 0 | 0 | 0 | /s/ Robert Pohly | Robert Pohly* |